Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
NCT05857566Phase 1Completed
- Sponsor
- Response Pharmaceuticals
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RDX-002 in drug-induced weight gain (2 arms), sponsored by Response Pharmaceuticals. Primary endpoints: Postprandial Triglyceride Absolute Area Under the Curve and Postprandial Triglyceride Incremental Area Under the Curve. Started May 2023; status: completed.
02
Drugs
RDX-002
03
Conditions
drug-induced weight gain
Beyond the preview
Go deeper on NCT05857566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857566.